Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2024 first-quarter earnings
Q1 2024-1x1.png

What you need to know about Johnson & Johnson’s 2024 first-quarter earnings

Here’s an infographic breakdown of the company’s first-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

This morning, Johnson & Johnson shared its 2024 first-quarter earnings report.

Since its founding in 1886 the company has been committed to innovation—today, more than 130,000 employees across the globe work to deliver solutions for patients around the world and to help profoundly impact health for humanity.

“This quarter’s solid financial results and the significant advancement of our pipeline further progressed our business toward future growth,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Our strong financial foundation and commitment to operational excellence enables us to continue to invest in innovation that delivers novel treatments for our patients, enhance our portfolio through strategic acquisitions, and return capital for our shareholders, as evidenced by our 62nd consecutive year of dividend increases announced today

For more details about the company’s 2024 first-quarter results and to read a message from Chairman and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.


Q1 2024 Earnings Infographic

Johnson & Johnson’s 2024 1st-quarter earnings

Read the earnings press release, which includes full financial data for the first quarter of 2024.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.